GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
-60
c/tirzepatide·posted 2 years ago by u/certified_reference

genuine question about SURMOUNT that I am slightly embarrassed to ask

Question

genuine question about SURMOUNT that I am slightly embarrassed to ask. If this has been answered properly somewhere, link me and I will delete.

Switching from semaglutide, since three people asked in this thread alone.

There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.

None of that is a recommendation. It is what the threads say, and the threads are not a clinic.

Week 73 was the first time the scale moved after a five-week stall. I changed nothing in that window.

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

Ask me anything specific. Anything general I will probably get wrong.

163 up / 223 down42% upvoted14 commentsid 14aajj23 Feb 2024

14 comments

14 in this archive, depth 5

best — the order this archive was captured in

u/dario_stanescu10 points·2 years ago

Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.

replysharereportpermalink
u/thyroid_tangent-10 points·2 years ago

the four-week step schedule is the label, not folklore

replysharereportpermalink
u/gentle_correctionnice about it10 points·2 years ago

hold the dose that works, the ladder is not a leaderboard

replysharereportpermalink
u/incretin_ivypharmacology8 points·2 years ago

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.

replysharereportpermalink
u/ahmed_fonseca8 points·2 years ago

The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.

replysharereportpermalink
u/curious_panel_only3 points·2 years ago

dual agonist, so the GIP arm is doing something the sema threads will not tell you about

replysharereportpermalink
u/discount_math_dm1 point·2 years ago

Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.

replysharereportpermalink
u/tidy_vialdrawer_pls2 points·2 years ago

Disagree with the conversion table. There is no validated equivalence between the two molecules and posting one as though there is does real damage.

replysharereportpermalink
u/swirl_dont_shakereconstitution1 point·2 years ago·edited

switching from sema is not a dose conversion, there is no clean equivalence

replysharereportpermalink
u/yusuf_ramos6 points·2 years ago

stepping every four weeks is a ceiling on speed, not a schedule you must hit

replysharereportpermalink
u/certified_referenceOPQC4 points·2 years ago

What step are you on and how long have you been there?

replysharereportpermalink
u/throwaway_wl20263 points·2 years ago

Held 7.5 for five months. Everyone kept asking when I was going to 10. The answer was never, because 7.5 was working.

replysharereportpermalink
u/mod_cold_roommod · c/coldchain2 points·2 years ago

Went 10 to 12.5 on the calendar and had the worst fortnight of the whole run. Dropped back to 10 and everything settled.

replysharereportpermalink
[removed]1 point·2 years ago

[removed by moderator]

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.